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Abstract
In vascular dementia (VaD) and Alzheimer’s disease (AD), cerebral hypoperfu-
sion and blood-brain barrier (BBB) leakiness contribute to brain damage. In this 
study, we have measured biochemical markers and mediators of cerebral hypop-
erfusion and BBB in the frontal (BA6) and parietal (BA7) cortex and underly-
ing white matter, to investigate the pathophysiology of vascular dysfunction in 
AD, VaD and mixed dementia. The ratio of myelin-associated glycoprotein to 
proteolipid protein-1 (MAG:PLP1), a post-mortem biochemical indicator of the 
adequacy of ante-mortem cerebral perfusion; the concentration of fibrinogen ad-
justed for haemoglobin level, a marker of blood-brain barrier (BBB) leakiness; the 
level of vascular endothelial growth factor-A (VEGF), a marker of tissue hypoxia; 
and endothelin-1 (EDN1), a potent vasoconstrictor, were measured by ELISA in 
the frontal and parietal cortex and underlying white matter in 94 AD, 20 VaD, 
33 mixed dementia cases and 58 age-matched controls. All cases were assessed 
neuropathologically for small vessel disease (SVD), cerebral amyloid angiopathy 
(CAA) severity, Aβ and phospho-tau parenchymal load, and Braak tangle stage. 
Aβ40 and Aβ42 were measured by ELISA in guanidine-HCl tissue extracts. We 
found biochemical evidence of cerebral hypoperfusion in AD, VaD and mixed 
dementia to be associated with SVD, Aβ level, plaque load, EDN1 level and Braak 
tangle stage, and to be most widespread in mixed dementia. There was evidence of 
BBB leakiness in AD—limited to the cerebral cortex and related to EDN1 level. 
In conclusion, abnormalities of cerebral perfusion and BBB function in common 
types of dementia can largely be explained by a combination of arteriolosclerosis, 
and Aβ-, tau- and endothelin-related vascular dysfunction. The relative contribu-
tions of these processes vary considerably both between and within the diseases.
K E Y W O R D S
Alzheimer’s disease, blood-brain barrier, cerebral hypoperfusion, mixed dementia, 
pathophysiology, vascular dementia
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1 |  INTRODUCTION
Cerebral ischaemia is the defining pathogenic process 
that underlies vascular dementia (VaD), in which the 
ischaemia is usually secondary to small vessel disease 
(SVD). Cerebrovascular abnormalities are also common 
in patients with AD: over 90% have cerebral amyloid 
angiopathy (CAA) (1–3), and up to 60% have ischaemic 
white matter damage (4–7). Cerebral hypoperfusion (8,9) 
and blood-brain barrier (BBB) breakdown (10) can be 
detected prior to the onset of dementia and contribute 
to the cognitive decline in the early stages of AD (11). 
In familial AD (FAD), regional cerebral blood flow is 
reduced at least 10–15 years before the predicted onset 
of clinical symptoms, the spread of cerebral hypoper-
fusion mirroring the deposition and spread of Aβ (12). 
Ischaemic white matter damage can be demonstrated 
up to 20 years prior to the onset of clinical symptoms in 
FAD (13), and most of this damage seems to be indepen-
dent of CAA (14).
A range of experimental studies has shown that brain 
ischaemia is likely to contribute to A β accumulation, 
through a combination of dysregulated processing and 
impaired clearance of A β [reviewed (15)]. In turn, A β 
peptides cause vasoconstriction, by inducing the con-
traction of pericytes (16) and probably vascular smooth 
muscle cells (17). Studies on rodent and human micro-
vascular endothelial cell monolayers (18,19), human APP 
transgenic mouse models (20) and in human post-mor-
tem brain tissue (21) also indicate that A β peptides di-
rectly impair BBB function, by reducing the expression 
of tight junction proteins including occludin and claudin. 
There is, therefore, a complex interrelationship between 
A β accumulation, reduced cerebral blood flow and BBB 
damage in AD in addition to VaD.
We previously explored the pathophysiology of cere-
bral ischaemia and BBB breakdown in VaD (22) and AD 
(23–25) by analysis of human post-mortem brain tissue. 
In those studies, ischaemic damage was quantified by 
comparing the levels of two myelin-proteins, myelin-as-
sociated protein (MAG) and proteolipid protein-1 (PLP-
1), that are differentially susceptible to changes in tissue 
oxygenation (26). As both MAG and PLP1 have a similar, 
slow turnover in vivo (with half-lives of over 3 months) 
and are stable for 72 hr or more under post-mortem con-
ditions (26), a reduction in the ratio of these proteins in 
post-mortem brain tissue indicates reduced perfusion of 
the tissue over a period of several months prior to death 
[reviewed in (27)]. We found the MAG:PLP1 ratio to be 
reduced in the white matter in VaD (22), and in the cere-
bral cortex in AD (23–25)—particularly in Braak tangle 
stage III and IV brains (24), i.e. at a relatively early stage 
of the disease. Reduced MAG:PLP1 in VaD and AD 
was generally associated with a concomitant increase in 
VEGF-A, an acute-response hypoxia-sensitive protein. 
MAG:PLP1 reduction and VEGF elevation correlated 
to some extent with the severity of cerebral amyloid 
angiopathy (CAA) and arteriosclerosis but were more 
strongly related to the level of endothelin-1 (EDN1) (24), 
a potent vasoconstrictor peptide, that we had shown pre-
viously to be increased in response to A β in AD (28). 
Within the precuneus, one of the earliest regions to show 
hypoperfusion in AD, the reduction of MAG:PLP1 was 
associated with loss of PDGFR β, a pericyte marker, and 
an increase in fibrinogen (FG) within the brain tissue, 
indicating BBB damage (25). In that study, brain FG 
level correlated with the amounts of A β40 and A β42 in 
the tissue.
In the present study, we have further analysed vas-
cular pathology and markers of vascular function 
in frontal and parietal cortex and white matter from 
neuropathologically defined cohorts of AD, VaD, 
mixed-dementia patients and age-matched controls, to 
identify disease-specific differences in the topography 
and pathophysiology of cerebral hypoperfusion and 
BBB breakdown. We have found cerebral hypoperfusion 
in AD, VaD and mixed dementia to be associated with 
small vessel disease, A β level, plaque load, EDN1 level 
and Braak tangle stage, and to be most widespread in 
mixed dementia. BBB leakiness was limited to the cere-
bral cortex in AD and was related to EDN1 level.
2 |  M ETHODS
2.1 | Brain tissue
Intact frozen post-mortem human brain tissue from 
four regions: (i) frontal cortex (Brodmann area 6) and 
(ii) superficial underlying frontal white matter; (iii) pre-
cuneus (medial parietal cortex) (Brodmann area 7) and 
(iv) superficial underlying parietal white matter, was ob-
tained from the South West Dementia Brain Bank for 
58 controls with no significant cognitive impairment, 
94 AD cases, 33 mixed dementia (AD and vascular) and 
20 vascular dementia (VaD) cases. Neuropathological 
changes, according to National Institute on Ageing-
Alzheimer's Association (NIA-AA) guidelines (29) were 
a sufficient explanation for Alzheimer’s disease. VaD 
cases had a clinical history of dementia, only the occa-
sional neuritic plaque and a Braak tangle stage of III or 
less, and histopathological evidence of multiple infarcts/
ischaemic lesions, moderate to severe atheroma and/or 
arteriosclerosis, in the absence of histopathological evi-
dence of other diseases likely to cause dementia. A neu-
ropathological diagnosis of mixed dementia was made 
for dementia patients found at autopsy to have multiple 
infarcts/ischaemic lesions and moderate to severe ather-
oma, whilst also fulfilling NIA-AA criteria for AD. We 
excluded cases with Lewy body pathology. At the time of 
collection of some of the older brains used in this study, 
we did not routinely screen all brains for TDP43 pathol-
ogy and so we have not included this in our analyses. 
Controls were age-matched, had no history of dementia, 
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few or no neuritic plaques, and no other neuropathologi-
cal abnormalities. Table 1 gives a summary of the cases 
included in each group.
2.2 | Assessment of Cerebral amyloid 
angiopathy (CAA) and small vessel disease 
(SVD) severity
CAA scores, based on the assessment of formalin-fixed 
paraffin-embedded sections of right frontal and parietal 
lobe immunolabelled with pan-Aβ 4G8 antibody (see 
below), were determined for the more recently donated 
cases in this study, or had been previously obtained (30). 
The CAA scores were based on the method of Olichney 
et al.,(31): 0 for vessels devoid of Aβ, 1 for limited deposits 
of vascular amyloid, 2 for the circumferential deposition 
of Aβ in several vessels, and 3 for severe and extensive 
CAA.
SVD (here used to refer specifically to arterioloscle-
rosis and excluding CAA) was scored in H&E-stained 
paraffin sections of right frontal and parietal lobe on a 
four-point semi-quantitative scale according to the level 
of arteriolar wall thickening and associated narrowing 
of vessel lumens: 0 for normal vessel wall thickness, 1 for 
slightly increased thickness, 2 for moderately increased 
thickness, and 3 for markedly increased thickness with 
concomitant reduction in many arteriolar lumina to less 
than 50% of the outer diameter of the vessel (26).
2.3 | Immunohistochemistry and analysis of 
parenchymal Aβ and tau load
The parenchymal Aβ and phospho-tau loads within 
the frontal (Brodmann area 6) and parietal cortex 
(Brodmann area 7) were determined in 7  µM sec-
tions immunolabelled with the pan-Aβ 4G8 antibody 
(32) and AT8 phospho-tau antibody (33), respectively. 
Both antibodies were optimised for use with an au-
tomated immunostainer (4G8 1:8000 and AT8 1:500 
in PBS; Ventana BenchMark ULTRA, Roche Tissue 
Diagnostics). Aβ and phospho-tau loads were quanti-
fied by field-fraction analysis using computer-based 
image analysis software (Image-Pro Plus 7, Media 
Cybernetics). The Aβ and phospho-tau measurements 
are summarised in Table S1.
2.4 | ELISA measurements of insoluble 
Aβ40 and Aβ42
Insoluble (guanidine-extractable) fractions of the ho-
mogenates for Aβ measurement by ELISA were prepared 
as previously reported (23–25,34–37). Sandwich ELISA 
kits for the measurement of Aβ40 and Aβ42 (DAB140, 
DAB142; R&D Systems) were used according to the 
manufacturer’s instructions. Brain homogenates were 
assayed in duplicate at 1:4000 dilution for cortical ho-
mogenates and 1:2500 for white matter homogenates. 
The levels of insoluble Aβ42 and Aβ40 in the frontal and 
parietal cortex and the underlying white matter are pre-
sented in Table S1.
2.5 | Biochemical assessment of 
vascular markers
2.5.1 | Brain tissue homogenisation
Brain tissue (200 mg) was homogenised in a Precellys ho-
mogeniser (2 × 15 s at 6000 rpm) with 5–10 silica beads 
(2.3 mm diameter) at 20% w/v in 1% SDS lysis buffer (1% 
w/v SDS, 0.1 M NaCl, 0.01 M Tris-HCl (pH 7.6), 1 µM 
PMSF and 1 µg/ml of aprotinin) for the measurement of 
MAG, PLP1, VEGF, FG, haemoglobin and EDN1 [as 
previously described (22–26)]. Homogenates were ali-
quoted and stored at −80°C prior to use.
TA B L E  1  Cohort summary
Control Alzheimer's disease Vascular dementia Mixed dementia
N 58 94 20 33
Age (y) ± SD 82.5 ± 9.1 77.7 ± 9.2 82.1 ± 7.8 87.3 ± 6.6
Gender (M:F) 33:25 51:43 10:10 9:24
PM delay (h) ± SD 41.5 ± 16.8 37.1 ± 19.3 44.2 ± 19.4 35.1 ± 16.7
Braak tangle stagea 
0–II 49 0 15 0
III and IV 8 12 5 10
V and VI 0 79 0 20
Note: Age and post-mortem (PM) delay are presented as the mean ± standard deviation (SD). The mean ages differed significantly between the groups (ANOVA, 
with Dunnett’s test): the AD cases were significantly younger (p < 0.001) and the mixed dementia cases significantly older (p < 0.05) than the controls. There were 
more females in the mixed dementia group ( χ 2 (df 3) = 7.9657, p = 0.047). The mean PM delay was shorter in the AD and mixed dementia groups than in controls 
but the difference was not statistically significant (ANOVA).
aBraak tangle stage was not available for 1 control, 3 AD cases and 3 mixed dementia cases. 
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2.6 | Myelin-associated glycoprotein 
(MAG) and proteolipid protein-1 (PLP1)
MAG level was measured in 1% SDS samples diluted 1 in 
10 in PBS using an in-house developed direct ELISA as 
previously described (22–26). PLP1 level was measured 
in 1% SDS extracted brain tissue homogenates, diluted 
1 in 10 in PBS, by use of a commercially available sand-
wich ELISA (SEA417Hu, USCN, Wuhan, China) as re-
ported previously (22–26).
2.7 | Vascular endothelial growth factor-A 
(VEGF)
VEGF was measured by sandwich ELISA with the 
Human VEGF DuoSet (R&D Systems, DY293B), ac-
cording to our previously published method (23-25).
2.8 | Fibrinogen (FG)
FG was measured in 1% SDS extracted brain tissue 
homogenates by a commercially available sandwich 
ELISA (FineTest EH3057 kit, Wuhan Fine Biotech Co., 
China) according to the manufacturer’s instructions. 
Homogenate samples in SDS buffer were assayed in du-
plicate at 1:256 dilution for white matter and 1:128 for cor-
tex. FG concentration was interpolated from a standard 
curve (1.563–100 ng/ml). As blood constitutes 4% and 5% 
of the volume of human brain tissue (38), FG measure-
ments were adjusted for the haemoglobin content of the 
samples (see below), so that variation between samples 
largely reflected differences in extravascular FG content.
2.9 | Haemoglobin colorimetric assay
Haemoglobin was measured by a colorimetric assay kit 
(Cayman Chemicals), modified for assay in 384-well 
ELISA plates. Haemoglobin detector and standard (both 
supplied) were prepared according to kit instructions. 
Standards (0.016–0.4 g/dl) and blanks were loaded at 50 
µL per well in triplicate. Samples (5 µl homogenate) and 
45 µl detector reagent were loaded in triplicate. The plate 
was sealed and incubated for 15 min at RT and then the 
absorbance read at 590 nm. Sample haemoglobin concen-
tration was determined by interpolation from the linear 
standard curve and adjusted for the dilution factor.
2.10 | Endothelin-1 (EDN1)
EDN1 was measured by QuantiGlo® ELISA for Human 
Endothelin-1 (R&D Systems, QET00B) as previously de-
scribed (24). Homogenate samples in SDS buffer were as-
sayed in duplicate at 1 mg/ml of total protein.
2.11 | Statistics
Unpaired two-tailed t-tests, or ANOVA with Dunnett’s or 
Bonferroni post hoc analysis was used for comparisons be-
tween groups, and Pearson's or Spearman's test to assess 
linear or rank-order correlation, as appropriate, with the 
help of SPSS version 21 (SPSS, Chicago) and GraphPad 
Prism version 8 (GraphPad Software, La Jolla, CA). p-val-
ues <0.05 were considered statistically significant.
3 |  RESU LTS
3.1 | Biochemical assessment of cerebral 
hypoperfusion in VaD, AD and mixed dementia
In the frontal and parietal cortex, mean MAG:PLP1 was 
highest in controls and lowest in VaD, although the dif-
ferences between VaD, AD, mixed dementia cases and 
controls were not statistically significant (Figure 1A,B). 
In frontal white matter, however, MAG:PLP1 was signif-
icantly lower in AD than controls (p < 0.01) (Figure 1C), 
and in parietal white matter, MAG:PLP1 was signifi-
cantly lower in all dementia groups than in age-matched 
controls: AD (p < 0.05), VaD (p < 0.01) and mixed de-
mentia (p < 0.05) (Figure 1D).
In all four regions examined, mean VEGF was low-
est in controls and highest in mixed dementia. However, 
only in the frontal cortex and parietal white matter was 
the difference between controls and mixed dementia 
cases statistically significant (p < 0.0001 and p < 0.001, 
respectively) (Figure 2A–D). MAG:PLP1 and VEGF 
correlated inversely across all regions (Figure S1) as we 
have previously shown (22,24).
3.2 | BBB breakdown in the cerebral cortex 
in AD
Fibrinogen (FG), adjusted for haemoglobin content, was 
significantly elevated in the frontal cortex (p  <  0.05), 
and was raised to a level approaching significance in 
the parietal cortex (p = 0.09) in AD compared to con-
trols (Figure 3A,B). FG in the frontal and parietal cortex 
was unaltered in VaD and mixed dementia. FG was also 
unchanged in the white matter in any of the dementia 
groups (Figure 3C,D).
3.3 | Cortical hypoperfusion related to Aβ42, 
EDN1 and SVD
To gain insight into potential drivers of cerebral hy-
poperfusion in the dementia subgroups, we investigated 
whether biochemical markers of cerebral hypoperfusion 
(MAG:PLP1 and VEGF) were associated with insolu-
ble Aβ level, parenchymal Aβ load, Braak tangle stage, 
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F I G U R E  1  Cerebral hypoperfusion 
in dementia. Scatterplots showing the 
ratio of myelin glycoprotein (MAG) to 
proteolipid protein-1 (PLP1) (MAG:PLP1) 
in the frontal and parietal cortex (A and 
B) and underlying white matter (C and 
D) in Alzheimer’s disease (AD), vascular 
dementia (VaD), mixed dementia (mixed) 
and age-matched controls (Control). 
MAG:PLP1 was reduced in frontal white 
matter in AD and in the parietal white 
matter in AD, VaD and mixed dementia. 
Each dot represents the mean value in one 
brain. The horizontal bars indicate the 
mean ± standard error of the mean (SEM). 
*p < 0.05, **p < 0.01
F I G U R E  2  Vascular-endothelial 
growth factor-A (VEGF-A) level is 
elevated in mixed (AD/VaD) dementia. 
Scatterplots showing the level of VEGF-A 
in the frontal and parietal cortex (A and 
B) and underlying white matter (C and 
D) in Alzheimer’s disease (AD), vascular 
dementia (VaD), mixed dementia (mixed) 
and age-matched controls (Control). 
VEGF-A was elevated in mixed dementia 
in the frontal cortex and parietal white 
matter. Each dot represents the mean value 
in one brain. The horizontal bars indicate 
the mean ± standard error of the mean 
(SEM). p-values <0.05 were considered 
statistically significant. ***p < 0.001, 
****p < 0.0001
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phospho-tau load, EDN1 level, and severity of SVD and 
CAA.
In the frontal and parietal cortex, MAG:PLP1 did not 
correlate with insoluble Aβ42 or Aβ40, or parenchymal 
Aβ. However, VEGF level correlated positively with paren-
chymal Aβ load and with insoluble Aβ42 (but not Aβ40) in 
the frontal cortex. No correlations between VEGF and Aβ 
level or load were observed in the parietal cortex (Table 2 
and Figure S2). Frontal and parietal MAG:PLP1 was not 
related to Braak tangle stage or parenchymal phospho-tau 
level. Frontal VEGF was increased in Braak stages III and 
IV vs 0-II, i.e. at an intermediate stage of progression of 
AD tangle pathology (Figure S3). MAG:PLP1 correlated 
inversely with EDN1 level in the frontal cortex but not 
the parietal cortex (Table 2 and Figure S3). VEGF level 
was strongly positively correlated with EDN1 in both the 
frontal and parietal cortex (Table 2). Frontal and parietal 
MAG:PLP1 and VEGF were not related to CAA severity. 
MAG:PLP1 tended to be reduced, and VEGF to be in-
creased, in relation to the severity of SVD, although these 
trends did not reach significance (Figure  S3). The rela-
tionships presented in Table 2 are shown as scatterplots in 
Figures S2 and S3.
3.4 | Subcortical white matter hypoperfusion 
related to EDN1 in the cortex and white 
matter, as well as Aβ parenchymal load and 
SVD severity
To gain insight into potential drivers of cerebral hypop-
erfusion of the white matter in the dementia subgroups, 
F I G U R E  3  Fibrinogen level is elevated 
in the cortex in Alzheimer’s disease. 
Fibrinogen level, adjusted for haemoglobin 
content was measured in the frontal and 
parietal cortex (A and B) and underlying 
white matter (C and D) in Alzheimer’s 
disease (AD), vascular dementia (VaD), 
mixed dementia (mixed) and age-matched 
controls (Control). Fibrinogen level was 
elevated in AD in the frontal cortex and 
to a level approaching significance in the 
parietal cortex. Each dot represents the 
mean value in one brain. The horizontal 
bars indicate the mean ± standard error 
of the mean (SEM). p-values <0.05 were 
considered statistically significant. 
*p < 0.05
TA B L E  2  Cortical cerebral hypoperfusion is associated with insoluble Aβ42 and parenchymal Aβ load, and endothelin-1
Cortical perfusion MAG:PLP1 VEGF
Pearson coefficients Frontal cortex Parietal cortex Frontal cortex Parietal cortex
Insoluble Aβ42 (pg/ml) r = −0.006 r = −0.069 r = 0.172* r = −0.038
Insoluble Aβ40 (pg/ml) r = 0.031 r = −0.061 r = −0.071 r = 0.031
Parenchymal Aβ load r = −0.022 r = 0.007 r = 0.249*** r = 0.011
Phospho-tau load r = −0.097 r = −0.066 r = 0.050 r = 0.032
EDN1 (pg/ml) r = −0.13* r = −0.037 r = 0.23** r = 0.293****
Note: Pearson’s correlation coefficients are shown for the relationship of MAG:PLP1 or VEGF to levels of insoluble Aβ42 and Aβ40, parenchymal Aβ (4G8) and 
phospho-tau (AT8) load, and endothelin-1 (EDN1) level.
*p < 0.05; **p < 0.01;  ***p < 0.001;  ****p < 0.0001 denote statistically significant correlations. 
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we assessed whether white matter MAG:PLP1 and 
VEGF were associated with insoluble Aβ level (in both 
the white matter itself and in the overlying cortex, as the 
blood supply to the white matter is carried through per-
forating arterioles that traverse the cortex), parenchymal 
Aβ load, Braak tangle stage, phospho-tau load, EDN1 
level in the white matter and overlying cortex, and sever-
ity of SVD and CAA.
MAG:PLP1 in the frontal white matter correlated 
inversely with insoluble Aβ42 level (but not Aβ40) in 
the cortex and with parenchymal Aβ load (Table 3 and 
Figure S4). White matter VEGF level did not vary sig-
nificantly with Aβ42, Aβ40 or parenchymal Aβ in the 
cortex but did correlate positively with insoluble Aβ42 
in the white matter in both the frontal and parietal lobes 
(Table  3 and Figure  S4). In both the frontal and pari-
etal white matter, MAG:PLP1 declined with increasing 
Braak tangle stage, being lower in BSV-VI than BS0-II 
(Figure S5), although white matter MAG:PLP1 did not 
vary significantly with phospho-tau level in the cortex. 
In contrast, white matter VEGF did not vary signifi-
cantly with the Braak tangle stage but did correlate in-
versely with phospho-tau load in both regions of cortex 
(Table 3 and Figure S5).
MAG:PLP1 was inversely related to EDN1 level in 
the same samples of frontal and parietal white matter 
(Figure 4A,B). Frontal white matter MAG:PLP1 was 
also inversely related to EDN1 in the overlying cortex 
(Table  3). VEGF correlated positively with EDN1 in 
the same samples of frontal and parietal white matter 
(Figure 4C,D) but not with EDN1 in the overlying cor-
tex. MAG:PLP1 in the frontal white matter was higher in 
cases with an SVD score of 0 than in those with a score 
of 1, 2, or 3 (p < 0.05 for all) but did not vary significantly 
between the other SVD subgroups (Table 3) or in relation 
to CAA severity in either region. VEGF in the white mat-
ter did not vary with the severity of CAA in the frontal 
or parietal lobe (Figure S5) or with SVD severity in the 
frontal lobe. However, VEGF was significantly higher in 
the parietal white matter in brains with severe SVD (i.e. 
a score of 3) than in those with less severe or absent SVD 
(Figure  S5). Figures  S4 and S5 show the relationships 
presented in Table 3 as individual scatterplots.
3.5 | Cortical BBB breakdown related to 
elevated EDN1
FG level, adjusted for haemoglobin content, corre-
lated positively with EDN1 level in the frontal cortex 
(Figure 5A) and white matter (Figure 5B). FG level within 
the parietal cortex was not related to EDN1 level in the 
overlying cortex but correlated weakly with EDN1 in 
the underlying white matter (Figure 5C,D). FG level 
in the white matter did not correlate significantly with 
EDN1 in the cortex or white matter in either the frontal 
or parietal lobe.
4 |  DISCUSSION
In this study, we have explored the distribution, and a 
range of possible contributors to, cerebral hypoperfusion 
and BBB breakdown in the parietal and frontal cortex 
and white matter in VaD, AD and mixed dementia. We 
found biochemical evidence of hypoperfusion in all three 
dementia subgroups but with differences in distribution 
and associated pathologies. In AD, evidence of hypop-
erfusion took the form of a reduced MAG:PLP1 ratio in 
the superficial subcortical white matter in both lobes. In 
VaD the reduction in MAG:PLP1 reached significance in 
the parietal white matter only. MAG:PLP1 was also re-
duced in the parietal white matter in mixed dementia but 
in this group there were also striking increases in VEGF 
in the frontal cortex as well as the parietal white matter. 
Across all cases, biochemical markers of cortical hypop-
erfusion and ischaemia, correlated with EDN1 level, pa-
renchymal Aβ load and insoluble Aβ42 level. Subcortical 
Sub-cortical perfusion
MAG:PLP1 VEGF
Frontal white matter Parietal white matter Frontal white matter Parietal white matter
Insoluble Aβ42 (pg/ml) r = −0.187* r = −0.096 r = 0.019 r = 0.055
Insoluble Aβ40 (pg/ml) r = −0.056 r = −0.006 r = −0.030 r = −0.01
Parenchymal Aβ load r = −0.180* r = −0.155* r = 0.118 r = −0.202*
WM—Insoluble Aβ42 r = 0.092 r = −0.067 r = 0.165* r = 0.140
Phospho-tau load r = −0.115 r = 0.000 r = −0.173** r = −0.219***
EDN1 (pg/ml) r = −0.189** r = −0.043 r = −0.051 r = −0.078
WM—EDN1 (pg/ml) r = −0.233*** r = −0.190** r = 0.173* r = 0.29**
Note: Pearson’s correlation coefficients are shown for the relationship of MAG:PLP1 or VEGF to levels of insoluble Aβ42 and Aβ40 in the white matter (WM) or 
cortex, parenchymal Aβ (4G8) and phospho-tau (AT8) load in the cortex, and white matter (WM) or cortical endothelin-1 (EDN1).
*p < 0.05; **p < 0.01; ***p < 0.001 denote statistically significant findings. 
TA B L E  3  Subcortical hypoperfusion is associated with insoluble Aβ42 level and parenchymal Aβ load, and endothelin-1
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F I G U R E  5  Increased cortical 
fibrinogen, a marker of BBB damage, 
is associated with elevated cortical and 
subcortical endothelin-1 in Alzheimer’s 
disease. (A–D) Scatterplots showing the 
relationship between fibrinogen level 
(adjusted for haemoglobin content) and 
cortical and subcortical endothelin-1 
(EDN1) levels. The solid line indicates best-
fit linear regression and the interrupted 
lines the 95% confidence intervals. Each 
point represents a separate brain. *p < 0.05, 
****p < 0.0001
F I G U R E  4  Cerebral hypoperfusion 
of the white matter in Alzheimer’s disease 
is related to endothelin-1 (EDN1). (A–D) 
Scatterplots showing the relationships 
between MAG:PLP1 (negative correlation) 
and VEGF (positive correlation) and 
endothelin-1 (EDN1) in the frontal and 
parietal white matter. The solid line 
indicates best-fit linear regression and 
the interrupted lines the 95% confidence 
intervals. Each point represents a separate 
brain. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001
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hypoperfusion was related to SVD severity but was also 
associated with the levels of EDN1 and insoluble Aβ42 
and with parenchymal Aβ load in the overlying cortex. 
FG was significantly elevated only in AD and only in 
the cortical regions and was related to the EDN1 level. 
These data suggest that there are multiple contributors 
to cerebral hypoperfusion in these common forms of de-
mentia, but that BBB breakdown is more specifically a 
feature of AD, perhaps related to the overproduction of 
EDN1 within the cerebral cortex.
We previously reported biochemical evidence of cere-
bral hypoperfusion in post-mortem brain tissue in VaD 
and AD, indicated by a reduction in MAG:PLP1 and an 
increase in VEGF (reviewed (15,27)). These biochemical 
changes are pronounced in deep cerebral white matter 
from people with severe SVD (26) but can also be demon-
strated in cortical regions and subcortical white matter in 
AD and VaD (22–24). In the medial parietal cortex, one 
of the first regions to demonstrate reduced blood flow in 
AD, MAG:PLP1 was much more reduced in Braak tan-
gle stages III and IV than in later-stage disease, and was 
strongly related to EDN1 and Aβ42 level but only mod-
estly to SVD and CAA severity (24). Cortical EDN1 and 
Aβ42 levels were also associated with hypoperfusion of 
the underlying frontal white matter perhaps as a result of 
EDN1-mediated constriction of perforating arterioles. 
Our present study largely confirms and extends those 
findings in a larger and more diverse cohort, emphasising 
the relationship between AD-related abnormalities (Aβ 
accumulation, Braak tangle stage and overproduction of 
EDN1) and both cortical and subcortical hypoperfusion, 
as well as the more modest but significant contribution 
of SVD to cerebral hypoperfusion in dementia.
One limitation of the present study is the modest size of 
the dementia subgroups, particularly the VaD subgroup. 
This is a reflection of the relative infrequency of neuro-
pathologically confirmed VaD as a sole explanation for 
dementia, as noted in other autopsy studies (39,40). A 
further limitation is that we did not analyse TDP-43 pa-
thology as a variable that might also be associated with 
cerebral hypoperfusion. There is evidence from recent 
studies that TDP-43 pathology may be associated with 
SVD (41,42) and it might, therefore, have been expected 
that MAG:PLP1 would be reduced and VEGF increased 
in brains showing TDP-43 pathology—this is something 
we will address in future studies. At present, it remains 
unclear what could be driving the reported association 
between TDP-43 pathology and SVD. In future studies 
we plan to investigate whether TDP-43 pathology, which 
tends to be most severe in the amygdala, hippocampus 
and medial temporal cortex, is associated with SVD, 
CAA and biochemical indicators of cerebral hypoperfu-
sion and vascular insufficiency, including BBB leakiness 
and pericytes loss, and to examine the topographic rela-
tionships between these vascular and neuronal pathol-
ogies. Last, post-mortem preservation of proteins may 
influence the interpretation of the biochemical data, 
although in previous studies we have shown that most 
of the key vascular markers that we measured, including 
MAG, PLP1, VEGF and EDN1, are stable up to 72 hr at 
4°C or even room temperature under conditions simulat-
ing post-mortem storage of human brain tissue (26,43).
In the present cohort, BBB leakiness, as indicated by 
increased FG, was limited to the frontal and parietal cor-
tex and was specific to AD. We previously demonstrated 
that FG level is elevated in the precuneus in AD and that 
the elevation is associated with markers of cerebral hy-
poperfusion and the level of Aβ (25). FG level was also 
elevated in the parietal cortex and underlying white mat-
ter in AD (25). Here we found that cortical FG level was 
elevated in AD, but not significantly in the underlying 
white matter. Cortical FG correlated with EDN1 level in 
the frontal cortex. There is evidence from other studies 
that EDN1 increases BBB permeability. The binding of 
EDN1 to the endothelin-1 type A receptor (EDNRA) was 
shown to increase leakiness of the BBB in rats and dogs 
(44,45), and cognitive deficit and BBB leakiness were 
reported in transgenic mice overexpressing EDN1 (46). 
EDN1 also regulates monocyte diapedesis across the 
human endothelium (47). Leung et al. showed that EDN1 
exacerbated BBB breakdown and oxidative damage after 
transient middle artery occlusion and that the damage 
was limited by the administration of EDNRA receptor 
antagonists (48). Upregulation of EDN1 production by 
oligomeric Aβ was also shown to cause pericyte-mediated 
capillary vasoconstriction (16) and to alter aquaporin-4 
distribution in astrocyte end-feet (49). Together, these 
studies underline the likely contribution of Aβ-induced 
overproduction of EDN1 to BBB breakdown and vas-
cular instability in AD. In contrast to AD, we did not 
find elevated FG levels in VaD in either the frontal or 
parietal cortex or underlying white matter. This was 
unexpected, in view of previous studies, indicating that 
vascular risk factors are associated with BBB leakiness 
in SVD and VaD in animal models and humans (50–52). 
Contributing factors may include the smaller size of the 
VaD cohort and the relatively advanced age of all of the 
cohorts, including the controls, many of which may have 
had some BBB leakiness independent of AD or VaD.
In conclusion, in the present study, we have identified 
disease-specific differences and commonalities in the 
topography and pathophysiology between biochemical 
markers of cerebral hypoperfusion and BBB breakdown 
across neuropathologically defined dementia sub-types. 
Differences in the severity and extent of vascular dys-
function in the cases studied largely reflect varied con-
tributions from arteriolosclerosis, and Aβ-, tau and 
endothelin-related vascular dysfunction.
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FIGURE S1 MAG:PLP1 and VEGF levels are inversely 
correlated in the frontal and parietal cortex and under-
lying white matter. (A-D) Scatterplots showing the rela-
tionship between MAG:PLP1 and VEGF in the frontal 
cortex (FC), parietal cortex (PC), frontal white matter 
(FWM) and parietal white matter (PWM). The solid line 
indicates best-fit linear regression and the interrupted 
lines the 95% confidence intervals. Each point represents 
a separate brain. Pearson’s correlation coefficients are 
shown only for statistically significant relationships. 
*p < 0.05, **p < 0.01
FIGURE S2 Relationships between markers of cerebral 
perfusion (MAG:PLP1 and VEGF) and Aβ (insoluble 
Aβ42 and Aβ40 levels, and parenchymal Aβ load) in 
frontal and parietal cortex. (A-L) Scatterplots showing 
the relationships of MAG:PLP1 and VEGF to Aβ42, 
Aβ40 and parenchymal Aβ load in the frontal cortex 
(FC) and parietal cortex (PC). The solid line indicates 
best-fit linear regression and the interrupted lines the 
95% confidence intervals. Each point represents a sep-
arate brain. Pearson’s correlation coefficients are shown 
only for statistically significant relationships. *p < 0.05, 
***p < 0.001
FIGURE S3 Markers of cerebral hypoperfusion 
(MAG:PLP1 and VEGF) in relation to Braak tangle 
stage, phospho-tau load, endothelin-1, CAA and SVD 
severity in frontal and parietal cortex. (A-D) Scatterplots 
showing MAG:PLP1 and VEGF-A in relation to Braak 
tangle stage (BS). (E-H) Scatterplots showing the rela-
tionship of MAG:PLP1 and VEGF-A to phospho-tau 
(AT8) load. (I-L) Scatterplots showing the relationship of 
MAG:PLP1 and VEGF-A to endothelin-1 (EDN1) level. 
(M-P) Scatterplots showing MAG:PLP1 and VEGF-A 
in relation to cerebral amyloid angiopathy (CAA) se-
verity. (Q-T) Scatterplots showing the relationship of 
MAG:PLP1 and VEGF-A to severity of small vessel dis-
ease (SVD). In the scatterplots subdivided according to 
Braak tangle stage, CAA or SVD severity, the horizontal 
bars represent the mean ± standard error of the mean 
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(SEM). One-way ANOVA with Bonferroni post-hoc 
analysis was used to determine if MAG:PLP1 or VEGF 
was altered in relation to Braak tangle stage (0-II, III-IV, 
V-VI), cerebral amyloid angiopathy (CAA) score (0, 1, 2, 
3) or small vessel disease (SVD) (0, 1, 2, 3). In the scat-
terplots, the solid line indicates best-fit linear regression 
and the interrupted lines the 95% confidence intervals. 
Pearson’s correlation coefficients are shown only for sta-
tistically significant relationships. Each point represents 
a separate brain. *p < 0.05, **p < 0.001, ****p < 0.0001
FIGURE S4 Relationship between markers of cerebral 
hypoperfusion (MAG:PLP1 and VEGF) and Aβ (insolu-
ble Aβ42 and Aβ40, and parenchymal Aβ load) in frontal 
and parietal white matter. (A-O) Scatterplots showing 
the relationship of MAG:PLP1 and VEGF to insoluble 
cortical Aβ42 and Aβ40 and parenchymal Aβ load, and 
to insoluble Aβ42 within the white matter. FC – fron-
tal cortex, PC – parietal cortex, FWM – frontal white 
matter, PWM – parietal white matter. The solid line 
indicates best-fit linear regression and the interrupted 
lines the 95% confidence intervals. Pearson’s correlation 
coefficients are shown only for statistically significant 
relationships. Each point represents a separate brain. 
*p < 0.05, **p < 0.01
FIGURE S5 Markers of cerebral hypoperfusion 
(MAG:PLP1, VEGF) in relation to Braak tangle stage, 
phospho-tau load, endothelin-1, CAA and SVD severity 
in frontal and parietal white matter. (A-D) Scatterplots 
showing MAG:PLP1 and VEGF-A in relation to Braak 
tangle stage (BS). (E-H) Scatterplots showing the rela-
tionship of MAG:PLP1 and VEGF-A to phospho-tau 
(AT8) load. (I-P) Scatterplots showing the relationship 
of MAG:PLP and VEGF-A to cortical and white mat-
ter endothelin-1 (EDN1) levels. (Q-T) Scatterplots show-
ing MAG:PLP1 and VEGF-A in relation to cerebral 
amyloid angiopathy (CAA) severity. (V-Y) Scatterplots 
showing MAG:PLP1 and VEGF-A in relation to small 
vessel disease (SVD). FC – frontal cortex, PC – parietal 
cortex, FWM – frontal white matter, PWM – parietal 
white matter. In the scatterplots subdivided according to 
Braak tangle stage, CAA or SVD severity, the horizontal 
bars represent the mean ± standard error of the mean 
(SEM). One-way ANOVA with Bonferroni post-hoc 
analysis was used to determine if MAG:PLP1 or VEGF 
was altered in relation to Braak tangle stage (0-II, III-IV, 
V-VI), cerebral amyloid angiopathy (CAA) score (0, 1, 2, 
3) or small vessel disease (SVD) (0, 1, 2, 3). In the scat-
terplots the solid line indicates best-fit linear regression 
and the interrupted lines the 95% confidence intervals. 
Pearson’s correlation coefficients are shown only for sta-
tistically significant relationships. Each point represents 
a separate brain. *p < 0.05, **p < 0.001, ****p < 0.0001
TABLE S1 Insoluble Aβ42 and Aβ40, and parenchymal 
Aβ and phospho-tau loads, in frontal and parietal cor-
tex. Aβ42 and Aβ40 levels were measured by ELISA in 
guandine-extracts representing the insoluble Aβ frac-
tion. Parenchymal Aβ was immunolabelled with 4G8 and 
phospho-tau was immunolabelled with AT8. Mean Aβ 
and phospho-tau loads were quantified by field-fraction 
analysis using computer-based image analysis software 
(Image-Pro Plus 7, Media Cybernetics). The values are 
shown as mean ± SEM. *significant difference between 
control and AD, #significant difference between AD 
and mixed dementia. #p < 0.05, ##p < 0.01, ***p < 0.001, 
****p < 0.0001
TABLE S2 List of MRC UK-BBN identifier numbers for 
cases used in this study. AD, Alzheimer’s disease; VaD, 
Vascular dementia
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